Yousif Capital Management LLC Purchases 2,830 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Yousif Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,816 shares of the company’s stock after acquiring an additional 2,830 shares during the quarter. Yousif Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $986,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of TEVA. Bourgeon Capital Management LLC grew its position in Teva Pharmaceutical Industries by 100.7% during the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock worth $12,134,000 after purchasing an additional 363,252 shares during the last quarter. Amundi grew its position in Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company’s stock worth $10,080,000 after purchasing an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd grew its position in Teva Pharmaceutical Industries by 9.4% during the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock worth $3,797,000 after purchasing an additional 19,447 shares during the last quarter. Jump Financial LLC grew its position in Teva Pharmaceutical Industries by 172.1% during the 1st quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock worth $20,373,000 after purchasing an additional 838,423 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in Teva Pharmaceutical Industries by 5.7% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock worth $38,487,000 after purchasing an additional 134,705 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $19.01 on Wednesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The firm has a fifty day moving average price of $19.00 and a 200 day moving average price of $17.18. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The stock has a market cap of $21.80 billion, a P/E ratio of -118.78, a P/E/G ratio of 1.07 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion during the quarter, compared to analysts’ expectations of $4.34 billion. During the same period in the previous year, the business posted $0.61 EPS. The business’s revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TEVA. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Friday, October 3rd. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $25.57.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.